LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
+0.48%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.11
From 52W high−60.49%
Volume2.27M
Market cap$344.59M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.11
From 52W high
−60.49%
Volume
2.27M
Market cap
$344.59M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
35.1
MomentumView details →
1D Return
+0.48%
YTD Return
−58.12%
SummaryUpdated Jun 1, 2026
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company founded in 2017 and headquartered in New York, New York. The company went public in November 2023 and focuses on developing gene therapies for both hereditary and acquired diseases. Lexeo operates in the biotechnology sector, specifically targeting genetic disorders through advanced gene therapy approaches using adeno-associated virus (AAV) vectors.
Similar companies
Latest newsMore news →
Lexeo Therapeutics reported its Q2 2026 financial results, with a net loss of $25.9 million and diluted EPS of -$0.30, and cash, cash equivalents and investments of $234.2 million as of June 30, 2026.40d agoThe FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lexeo Therapeutics for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy, based on interim clinical data from an ongoing Phase I/II trial.46d ago